Blood product recipients, and the organizations that represent them, are perfectly justified to question developments that may affect the products they use.
Blood-borne transmission can be through needle-sharing during intravenous drug use, needle stick injury, transfusion of contaminated blood or blood product, or medical injections with unsterilised equipment.